The therapeutic strategy targeting CAFs-mediated FGF5/FGFR2 axis in TME might augment DDP sensitivity and reduce the effective dose of DDP, thus decreasing the side effects of DDP in NPC. This evidence concerns the gene FGFR2 and nasopharyngeal carcinoma.